Introduction
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Overview
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Development
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Assessment
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Drug Profiles
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Discontinued Products
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Product Development Milestones
Appendix

List of Tables
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..3), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Products under Development by Companies, H2 2020 (Contd..3), H2 2020
Products under Development by Companies, H2 2020 (Contd..4), H2 2020
Products under Development by Companies, H2 2020 (Contd..5), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by 4D Pharma Plc, H2 2020
Pipeline by 4SC AG, H2 2020
Pipeline by Chengdu Jinrui Foundation Biotechnology Co Ltd, H2 2020
Pipeline by Curis Inc, H2 2020
Pipeline by GNT Biotech and Medicals Corp, H2 2020
Pipeline by Kdac Therapeutics Inc, H2 2020
Pipeline by Medivir AB, H2 2020
Pipeline by Merck & Co Inc, H2 2020
Pipeline by Oceanyx Pharmaceuticals Inc, H2 2020
Pipeline by OnKure Inc, H2 2020
Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, H2 2020
Pipeline by Shuttle Pharmaceuticals Inc, H2 2020
Pipeline by Syndax Pharmaceuticals Inc, H2 2020
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Dormant Products, H2 2020 (Contd..3), H2 2020
Discontinued Products, H2 2020
Discontinued Products, H2 2020 (Contd..1), H2 2020

List of Figures
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned
• 4D Pharma Plc
• 4SC AG
• Chengdu Jinrui Foundation Biotechnology Co Ltd
• Curis Inc
• GNT Biotech and Medicals Corp
• Kdac Therapeutics Inc
• Medivir AB
• Merck & Co Inc
• Oceanyx Pharmaceuticals Inc
• OnKure Inc
• Shenzhen Chipscreen Biosciences Co Ltd
• Shuttle Pharmaceuticals Inc
• Syndax Pharmaceuticals Inc
• Zhejiang Hisun Pharmaceutical Co Ltd